They have been talking about the oral program since I first started following the company (at the reverse merger with Tranzyme) which is several years now so I wouldn't read too much into.
I agree with Dew about the Ravicti not exactly being derisking since it was a completely different trial (Dew may have other reasons as well). Here is the paper on it if anyone is interested. http://onlinelibrary.wiley.com/doi/10.1002/hep.26611/full If anything it may be more supportive for the oral program. Linda indicated at a recent conference if the IV would fail but secondary/supportive data are encouraging they would proceed with the oral.
To me the most bullish thing is the interim resize suggested a treatment benefit in the 1.5 - 2 day range (according to the company). While the company says one day is compelling I am not so sure at the already lower price then I expected I'd feel more comfortable nearer to 2 days.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.